GlassScriptPhysician profile
William O Thompson
NPI 1669427878
$7,086.84
in general payments reported to CMS, 2019-2025
32 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $1,003 · 2021: $1,726 · 2022: $856 · 2023: $673 · 2024: $943 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $890.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $802.62 | 2019-2025 | Rybelsus, Ozempic |
| Stryker Corporation | $788.41 | 2021 | |
| Lilly USA, LLC | $561.97 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $529.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $476.15 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $395.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $328.12 | 2019-2024 | Capvaxive, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.52 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $310.08 | 2019-2021 | |
| Abbvie INC. | $308.96 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $198.71 | 2019-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $132.36 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $131.64 | 2019-2022 | |
| Astellas Pharma US INC | $128.76 | 2020-2024 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $126.07 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.67 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $71.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $64.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.49 | 2022-2025 | |
| Abbott Laboratories | $54.17 | 2021-2025 | Id Now Instrument |
| Allergan, INC. | $46.94 | 2020 | |
| Amarin Pharma, INC. | $41.21 | 2019-2020 | |
| Ucb, INC. | $38.02 | 2023 | Nayzilam |
| Biohaven Pharmaceuticals, INC. | $36.06 | 2021 | |
| Axsome Therapeutics, INC. | $24.69 | 2025 | Auvelity |
| Corcept Therapeutics | $20.11 | 2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $19.93 | 2024 | Ultomiris |
| Linus Health, INC. | $19.27 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.56 | 2025 | |
| Sanofi Pasteur INC. | $13.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.